PC14586 在携带 p53 Y220C 突变的晚期实体瘤患者中的评估
一项 1/2 期开放标签多中心研究,以评估 PC14586 在携带 p53 Y220C 突变的晚期实体瘤患者中的安全性、耐受性、药代动力学、药效学和疗效 (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.
研究概览
地位
条件
详细说明
Rezatapopt is a first-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation.
The primary objective of Phase 2 Monotherapy is to evaluate the efficacy of rezatapopt at the Recommended Phase 2 Dose (RP2D) including the Overall Response Rate (ORR) in the Ovarian Cancer Cohort and the ORR across all cohorts as determined by blinded independent central review. Secondary objectives of Phase 2 are to characterize the safety, pharmacokinetic (PK) properties, quality of life, and other efficacy measures of PC14586 rezatapopt at the RP2D. Enrollment is open for the Phase 2 Monotherapy portion of the study.
The primary objective of Phase 1 Monotherapy is to establish the maximum tolerated dose (MTD) and RP2D of rezatapopt. Secondary objectives are to characterize the PK properties, safety and tolerability, and to assess preliminary efficacy including ORR. Enrollment into Phase 1 Monotherapy is complete.
The primary objective of Phase 1b Combination Therapy is to establish the MTD/RP2D of rezatapopt when administered in combination with pembrolizumab. Secondary objectives of Phase 1b Combination Therapy are to characterize PK, safety and tolerability, and to assess preliminary efficacy of rezatapopt when administered in combination with pembrolizumab, including ORR. Enrollment into Phase 1b Combination Therapy is complete.
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:PMV Pharma Clinical Study Information Center
- 电话号码:(609) 235-4038
- 邮箱:clinicaltrials@pmvpharma.com
学习地点
-
-
Baden-Wurttemberg
-
Heidelberg、Baden-Wurttemberg、德国
- 招聘中
- Nationale Centrum für Tumorerkrankungen (NCT) Heidelberg
-
接触:
- Martin Haag, MD
-
-
Bavaria
-
Augsburg、Bavaria、德国
- 招聘中
- Universitätsklinikum Augsburg
-
接触:
- Rainer Claus, MD
-
-
Free and Hanseatic City of Hamburg
-
Hamburg、Free and Hanseatic City of Hamburg、德国
- 招聘中
- Asklepios Klinik Altona
-
接触:
- Dirk Arnold, MD
-
-
Hesse
-
Frankfurt am Main、Hesse、德国
- 撤销
- Universitätsklinikum Frankfurt
-
-
North Rhine-Westphalia
-
Essen、North Rhine-Westphalia、德国
- 招聘中
- Universitätsklinikum Essen
-
接触:
- Marcel Wiesweg, MD
-
-
-
-
-
Milan、意大利
- 招聘中
- Humanitas San Pio X
-
接触:
- Domenica Lorusso, MD
-
Naples、意大利、80131
- 招聘中
- IRCCS - lstituto Nazionale Tumori - Fondazione G. Pascale
-
接触:
- Anna Passarelli, MD
-
-
Lazio
-
Rome、Lazio、意大利
- 招聘中
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
-
接触:
- Anna Fagotti, MD
-
Rome、Lazio、意大利
- 招聘中
- Istituti Fisioterapici Ospitalieri - Istituto Nazionale Tumori Regina Elena
-
接触:
- Lorenza Landi, MD
-
-
Lombardy
-
Milan、Lombardy、意大利
- 招聘中
- ASST Grande Ospedale Metropolitano Niguarda
-
接触:
- Salvatore Siena, MD
-
Milan、Lombardy、意大利
- 招聘中
- Fondazione IRCCS Istituto Nazionale Dei Tumori
-
接触:
- Massimo Di Nicola, MD
-
Milan、Lombardy、意大利
- 招聘中
- Istituto Europeo Di Oncologia
-
接触:
- Giuseppe Curigliano, MD
-
Rozzano、Lombardy、意大利
- 招聘中
- Istituto Clinico Humanitas
-
接触:
- Armando Santoro, MD
-
-
Torino
-
Candiolo、Torino、意大利
- 招聘中
- Fondazione del Piemonte per l'Oncologia (IRCCS)
-
接触:
- Chiara Lazzari, MD
-
-
-
-
-
Kent Ridge、新加坡
- 招聘中
- National University Hospital
-
接触:
- David Shao Peng Tan, MD
-
Singapore、新加坡、168582
- 招聘中
- National Cancer Center of Singapore
-
接触:
- Tira Tan, MD
-
-
-
-
-
Lyon、法国
- 招聘中
- Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer
-
接触:
- Isabelle Ray-Coquard, MD
-
Nîmes、法国、30900
- 招聘中
- CHU de Nîmes
-
接触:
- Frédéric Fiteni, MD, PhD
-
Vandœuvre-lès-Nancy、法国、54519
- 招聘中
- Institute Cancer De Lorraine
-
接触:
- Aurélien Lambert, MD
-
-
Bas-Rhin
-
Strasbourg、Bas-Rhin、法国
- 招聘中
- ICANS - Institut de cancérologie Strasbourg Europe
-
接触:
- Lauriane Eberst, MD
-
-
Gironde
-
Bordeaux、Gironde、法国
- 招聘中
- Institut Bergonie
-
接触:
- Veronique Debien, MD
-
-
Haute-Garonne
-
Toulouse、Haute-Garonne、法国
- 招聘中
- Institut Claudius Regaud
-
接触:
- Carlos-Alberto Gomez-Roca, MD
-
-
Loire-Atlantique
-
Saint-Herblain、Loire-Atlantique、法国
- 招聘中
- EDOG Institut de Cancerologie de l'Ouest
-
接触:
- Jean-Sebastien Frenel, MD
-
-
Puy-de-Dôme
-
Clermont-Ferrand、Puy-de-Dôme、法国
- 招聘中
- Centre Jean Perrin
-
接触:
- Xavier Durando, MD
-
-
Val-de-Marne
-
Villejuif、Val-de-Marne、法国
- 招聘中
- Institut Gustave Roussy
-
接触:
- Yohann Loriot, MD
-
-
-
-
New South Wales
-
Camperdown、New South Wales、澳大利亚
- 招聘中
- Chris O'Brien Lifehouse Hospital
-
接触:
- Peter Grimison, MD
-
-
Queensland
-
South Brisbane、Queensland、澳大利亚
- 招聘中
- Mater Cancer Care Centre
-
接触:
- Catherine Shannon, MD
-
-
South Australia
-
Bedford Park、South Australia、澳大利亚
- 招聘中
- Flinders Medical Center
-
接触:
- Shawgi Sukumaran, MD
-
-
Victoria
-
Clayton、Victoria、澳大利亚
- 招聘中
- Monash Medical Centre
-
接触:
- Sophia Frentzas, MD
-
-
Western Australia
-
Nedlands、Western Australia、澳大利亚
- 招聘中
- Linear Clinical Research
-
接触:
- Michael Millward, MD
-
-
-
-
California
-
Irvine、California、美国、92868
- 撤销
- University of California Irvine Chao Family Comprehensive Cancer Center
-
La Jolla、California、美国、92093
- 招聘中
- University of San Diego Moores Cancer Center
-
接触:
- Shumei Kato, MD
-
Los Angeles、California、美国、90033
- 招聘中
- USC Norris Comprehensive Cancer Center
-
接触:
- Anthony El-Khoueiry, MD
-
Los Angeles、California、美国、90024
- 招聘中
- UCLA Jonsson Comprehensive Cancer Center
-
接触:
- Gottfried Konecny, MD
-
-
Colorado
-
Denver、Colorado、美国、80218
- 招聘中
- Rocky Mountain Cancer Center
-
接触:
- Allen Cohn, MD
-
-
Connecticut
-
New Haven、Connecticut、美国、06519
- 招聘中
- Yale Cancer Center
-
接触:
- Patricia LoRusso, MD
-
-
Delaware
-
Newark、Delaware、美国、19713
- 招聘中
- Medical Oncology Hematology Consultants
-
接触:
- Jamal Misleh, MD
-
-
Florida
-
Miami、Florida、美国、33136
- 招聘中
- University of Miami - Sylvester Comprehensive Cancer Center
-
接触:
- Gilberto de Lima Lopes Jr., MD
-
Orlando、Florida、美国、32803
- 招聘中
- Advent Health
-
接触:
- Robert Holloway, MD
-
Port Charlotte、Florida、美国、33980
- 招聘中
- Florida Cancer Specialists South
-
接触:
- Ivor Percent, MD
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- 招聘中
- Massachusetts General Hospital
-
接触:
- Aparna Parikh, MD
-
Boston、Massachusetts、美国、02215
- 招聘中
- Dana Farber Cancer Institute
-
接触:
- Geoffrey Shapiro, MD, PhD
-
-
Michigan
-
Detroit、Michigan、美国、48201
- 完全的
- Karmanos Cancer Institute
-
-
New York
-
New York、New York、美国、10065
- 招聘中
- Memorial Sloan Kettering
-
接触:
- Alison Schram, MD
-
New York、New York、美国、10032
- 尚未招聘
- Columbia University Medical Center
-
接触:
- June Hou, MD
-
-
North Carolina
-
Durham、North Carolina、美国、27705
- 招聘中
- Duke University
-
接触:
- Niharika Mettu, MD, PhD
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- 招聘中
- The Cleveland Clinic Taussig Cancer Center
-
接触:
- Dale Shepard, MD
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104
- 招聘中
- University of Oklahoma
-
接触:
- Debra Richardson, MD
-
-
Oregon
-
Portland、Oregon、美国、97210
- 招聘中
- Oregon Health & Science University (OHSU)
-
接触:
- Shivaani Kummar, MD
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- 招聘中
- Abramson Cancer Center of the University of Pennsylvania
-
接触:
- Lainie Martin, MD
-
Pittsburgh、Pennsylvania、美国、15213
- 招聘中
- University of Pittsburgh Medical Center
-
接触:
- Sarah Taylor, MD, PhD
-
York、Pennsylvania、美国、17403
- 招聘中
- WellSpan York Cancer Center
-
接触:
- Ikechukwu Akunyili, MD
-
-
South Carolina
-
Charleston、South Carolina、美国、29425
- 终止
- Medical University of South Carolina
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- 招聘中
- Sarah Cannon Research Institute
-
接触:
- Melissa Johnson, MD
-
-
Texas
-
Austin、Texas、美国、78705
- 招聘中
- New Experimental Therapeutics - NEXT Oncology
-
接触:
- David Sommerhalder, MD
-
Bedford、Texas、美国、76022
- 招聘中
- Texas Oncology
-
接触:
- Terrence Wong, MD
-
Dallas、Texas、美国、75390
- 招聘中
- UT Southwest Simmons Cancer Center
-
接触:
- David Miller, MD
-
Houston、Texas、美国、77030
- 招聘中
- The University of Texas MD Anderson Cancer Center
-
接触:
- Ecaterina Dumbrava, MD
-
San Antonio、Texas、美国、78229
- 招聘中
- New Experimental Therapeutics of San Antonio - NEXT Oncology
-
接触:
- David Sommerhalder, MD
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- 招聘中
- Virginia Cancer Specialists
-
接触:
- Alexander Spira, MD
-
-
Washington
-
Seattle、Washington、美国、98109
- 招聘中
- University of Washington, Fred Hutchinson Cancer Center
-
接触:
- Andrew Coveler, MD
-
-
Wisconsin
-
Madison、Wisconsin、美国、53705
- 招聘中
- University of Wisconsin Carbone Cancer Center
-
接触:
- Nataliya Uboha, MD, PhD
-
-
-
-
Middlesex
-
London、Middlesex、英国
- 招聘中
- Sarah Cannon Research Institute UK
-
接触:
- Elisa Fontana, MD, PhD
-
-
Tyne and Wear
-
Newcastle upon Tyne、Tyne and Wear、英国
- 招聘中
- Freeman Hospital
-
接触:
- Alastair Greystoke, MB ChB PhD
-
-
-
-
-
Barcelona、西班牙
- 招聘中
- NEXT Oncology-Hospital Quironsalud Barcelona
-
接触:
- Elena Garralda, MD
-
Barcelona、西班牙
- 招聘中
- Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON
-
接触:
- Lorena Farinas, MD
-
Madrid、西班牙、28041
- 招聘中
- Hospital Universitario 12 de Octubre
-
接触:
- Santiago Ponce Aix, MD
-
Rioja、西班牙
- 招聘中
- START Rioja
-
接触:
- Jorge Luis Ramon Patino, MD
-
Valencia、西班牙
- 招聘中
- Hospital Clinico Universitario de Valencia
-
接触:
- José Alejandro Pérez Fidalgo, MD
-
-
Madrid
-
Madrid、Madrid、西班牙
- 招聘中
- START MADRID_Hospital Universitario Fundacion Jimenez Diaz
-
接触:
- Victor Moreno Garcia, MD
-
Madrid、Madrid、西班牙
- 招聘中
- START MADRID_Hospital Universitario HM Sanchinarro - CIOCC
-
接触:
- Irene Moreno, MD
-
-
-
-
-
Seoul、韩国
- 招聘中
- Samsung Medical Center
-
接触:
- Chel Hun Choi, MD
-
Seoul、韩国
- 招聘中
- Asan Medical Center
-
接触:
- Dae Ho Lee, MD
-
Seoul、韩国
- 招聘中
- Seoul University Hospital
-
接触:
- Seock-Ah Im, MD
-
Seoul、韩国
- 招聘中
- Severance Hospital Yonsei University
-
接触:
- Jung-Yun Lee, MD
-
Seoul、韩国
- 招聘中
- National Cancer Center
-
接触:
- Myong Cheol Lim, MD, PhD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval.
- Locally advanced or metastatic solid malignancy with a TP53 Y220C mutation
- Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
- Previously treated with one or more lines of anticancer therapy and progressive disease
- Adequate organ function
- Measurable disease per RECIST v1.1 (Phase 2)
Additional Criteria for Inclusion in Phase 1b (rezatapopt) + pembrolizumab combination)
- Anti-PD-1/PD-L1 naive or must have progressed on treatment
- Measurable disease
Exclusion Criteria:
- Anti-cancer therapy within 21 days (or 5 half-lives) of receiving the study drug
- Radiotherapy within 14 days of receiving the study drug
- Primary CNS tumor
- History of leptomeningeal disease or spinal cord compression
- Brain metastases, unless neurologically stable and do not require steroids to treat associated neurological symptoms
- Stroke or transient ischemic attack within 6 months prior to screening
- Heart conditions such as unstable angina within 6 months prior to screening, uncontrolled hypertension, a heart attack within 6 months prior to screening, congestive heart failure, prolongation of QT interval, or other rhythm abnormalities
- Strong CYP3A4 inducers and strong CYP2C9 inhibitors/inducers within 14 days of first dose of rezatapopt
- History of gastrointestinal (GI) disease that may interfere with absorption of study drug or patients unable to take oral medication
- History of prior organ transplant
- Known, active malignancy, except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer
- Known, active uncontrolled Hepatitis B, Hepatitis C, or human immunodeficiency virus infection
Additional Criteria for Exclusion from Phase 2 (rezatapopt monotherapy)
- Known KRAS mutation, defined as a single nucleotide variant (SNV) (Phase 2). Exception: Ovarian cancer patients with a known KRAS SNV are permitted.
Additional Criteria for Exclusion from Phase 1b (rezatapopt) + pembrolizumab combination)
- Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and discontinued from that treatment due to a Grade 3 or higher immune-related AE (irAE)
- Received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention
- Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy within 7 days prior to the first dose of study drug
- Hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients
- Active autoimmune disease that has required systemic treatment in past 2 years
- History of radiation pneumonitis
- History of (non-infectious) or active pneumonitis / interstitial lung disease that required steroids
- Active infection requiring systemic therapy
- Known history of HIV infection
- Has previously received rezatapopt
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Phase 1 Monotherapy Dose Escalation
Multiple dose levels of daily oral rezatapopt will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of rezatapopt to recommend a Phase 2 dose (RP2D). |
First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.
其他名称:
|
|
实验性的:Phase 1b Combination Therapy Dose Escalation, Part 1
Multiple dose levels of daily oral rezatapopt in combination with a stable dose of pembrolizumab (200 mg IV q3 weeks) will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of PC14586 to recommend a Phase 2 dose (RP2D) of rezatapopt when administered in combination with pembrolizumab. |
First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.
其他名称:
Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.
其他名称:
|
|
实验性的:Phase 1b Combination Therapy Dose Expansion, PD(L)-1 naive patients
Additional (expansion of) participants will enroll at the RP2D of daily oral PC14586 (INN: rezatapopt) when administered in combination with pembrolizumab (200 mg IV q3 weeks) for continued evaluation. Participants will have advanced solid tumors harboring a p53 Y220C mutation and are PD(L)-1 naive patients. |
First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.
其他名称:
Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.
其他名称:
|
|
实验性的:Phase 1b Combination Therapy Dose Expansion, PD(L)-1 relapsed/refractory patients
Additional (expansion of) participants will enroll at the RP2D of daily oral rezatapopt when administered in combination with pembrolizumab (200 mg IV q3 weeks) for continued evaluation. Participants will have advanced solid tumors harboring a p53 Y220C mutation and are PD(L)-1 relapsed/refractory patients. |
First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.
其他名称:
Participants receive pembrolizumab 200 mg by intravenous (IV) infusion over 30 minutes.
其他名称:
|
|
实验性的:Phase 2 Monotherapy Dose Expansion, Ovarian Cancer Cohort
Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Ovarian Cancer Cohort participants will have locally advanced or metastatic ovarian cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1. |
First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.
其他名称:
|
|
实验性的:Phase 2 Monotherapy Dose Expansion, Lung Cancer Cohort
Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Lung Cancer Cohort participants will have locally advanced or metastatic lung cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1. |
First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.
其他名称:
|
|
实验性的:Phase 2 Monotherapy Dose Expansion, Breast Cancer Cohort
Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Breast Cancer Cohort participants will have locally advanced or metastatic breast cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1. |
First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.
其他名称:
|
|
实验性的:Phase 2 Monotherapy Dose Expansion, Endometrial Cancer Cohort
Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Endometrial Cancer Cohort participants will have locally advanced or metastatic endometrial cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1. |
First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.
其他名称:
|
|
实验性的:Phase 2 Monotherapy Dose Expansion, Other Solid Tumors Cohort
Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Other Solid Tumors Cohort participants will have locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1. |
First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Phase 1 Monotherapy (Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt
大体时间:40 months
|
Number of participants with treatment related adverse events |
40 months
|
|
Phase 1 Monotherapy (Dose Escalation): Establish the Recommended Phase 2 Dose (RP2D)
大体时间:30 months
|
RP2D will be determined using available safety and pharmacokinetics and pharmacodynamics data |
30 months
|
|
Phase 1 Monotherapy (Dose Escalation): Establish the maximum tolerated dose (MTD) (Phase 1)
大体时间:The first 28 days of treatment (Cycle 1) per patient
|
Incidence of dose limiting toxicities (DLTs) during the first 28 days of treatment with rezatapopt |
The first 28 days of treatment (Cycle 1) per patient
|
|
Phase 1b Combination Therapy (Part 1: Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt when administered in combination with pembrolizumab
大体时间:18 months for treatment arm
|
Number of participants with treatment related adverse events |
18 months for treatment arm
|
|
Phase 1b Combination Therapy (Part 1: Dose Escalation): Establish the maximum tolerated dose (MTD) of rezatapopt when administered in combination with pembrolizumab
大体时间:The first 28 days of combination treatment arm (starting on Day -7) per patient
|
Incidence of dose limiting toxicities (DLTs) during the first 28 days of treatment with rezatapopt |
The first 28 days of combination treatment arm (starting on Day -7) per patient
|
|
Phase 1b Combination Therapy (Part 1: Dose Escalation): Establish the Recommended Phase 2 Dose (RP2D) of rezatapopt when administered in combination with pembrolizumab
大体时间:18 months
|
RP2D will be determined using available safety and pharmacokinetics and pharmacodynamics data |
18 months
|
|
Phase 1b Combination Therapy (Part 2: Dose Expansion): Determine the number and type of adverse events to characterize the safety of rezatapopt when administered in combination with pembrolizumab
大体时间:12 months for treatment arm
|
Number of participants with treatment related adverse events |
12 months for treatment arm
|
|
Phase 2 Monotherapy (Dose Expansion): Response rate assessment to evaluate the clinical activity / efficacy of rezatapopt
大体时间:34 months
|
Overall response rate in accordance with Response Evaluation Criteria (RECIST) v.1.1 as assessed by independent review across all cohorts |
34 months
|
|
Phase 2 Monotherapy (Dose Expansion): Response rate assessment to evaluate the clinical activity / efficacy of rezatapopt in ovarian cancer patients
大体时间:34 months
|
Overall response rate in accordance with Response Evaluation Criteria (RECIST) v.1.1 as assessed by independent review in the ovarian cancer cohort |
34 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Phase 1 Monotherapy: PK profile of rezatapopt - Peak concentration (Cmax)
大体时间:Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt |
Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
|
Phase 1 Monotherapy: PK profile of rezatapopt - Time of peak concentration (Tmax)
大体时间:Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt |
Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
|
Phase 1 Monotherapy: PK profile of rezatapopt - Area under the plasma concentration-time curve from time zero to time of last sampling timepoint (AUC0-t)
大体时间:Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt |
Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
|
Phase 1 Monotherapy: PK profile of rezatapopt - Area under the plasma concentration-time curve in one dosing interval (AUCtau)
大体时间:Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt |
Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
|
Phase 1 Monotherapy: PK profile of rezatapopt - Trough observed concentrations (Ctrough/Ctau)
大体时间:Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt |
Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
|
Phase 1 Monotherapy: Blood plasma assessment to describe the concentration of PC14586 and metabolites when rezatapopt is administered orally.
大体时间:Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
Blood plasma concentration |
Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
|
Phase 1 Monotherapy (Dose Escalation): Overall Response Rate per RECIST v1.1 or PCWG3 modified RECIST v1.1
大体时间:41 months for study (end of Phase 1)
|
Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent |
41 months for study (end of Phase 1)
|
|
Phase 1 Monotherapy (Dose Escalation): Time to Response per RECIST v1.1 or PCWG3 modified RECIST v1.1
大体时间:41 months for study (end of Phase 1)
|
Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent |
41 months for study (end of Phase 1)
|
|
Phase 1 Monotherapy (Dose Escalation): Duration of Response per RECIST v1.1 or PCWG3 modified RECIST v1.1
大体时间:41 months for study (end of Phase 1)
|
Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent |
41 months for study (end of Phase 1)
|
|
Phase 1 Monotherapy (Dose Escalation): Disease Control Rate per RECIST v1.1 or PCWG3 modified RECIST v1.1
大体时间:41 months for study (end of Phase 1)
|
Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent |
41 months for study (end of Phase 1)
|
|
Phase 1 Monotherapy (Dose Escalation): Progression Free Survival per RECIST v1.1 or PCWG3 modified RECIST v1.1
大体时间:41 months for study (end of Phase 1)
|
Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent |
41 months for study (end of Phase 1)
|
|
Phase 1 Monotherapy (Dose Escalation): Overall Survival
大体时间:41 months for study (end of Phase 1)
|
Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent |
41 months for study (end of Phase 1)
|
|
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Peak concentration (Cmax)
大体时间:Approximately 12 months per patient (30 months for treatment arm)
|
Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt |
Approximately 12 months per patient (30 months for treatment arm)
|
|
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Time of peak concentration (Tmax)
大体时间:Approximately 12 months per patient (30 months for treatment arm)
|
Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt |
Approximately 12 months per patient (30 months for treatment arm)
|
|
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Area under the plasma concentration-time curve from time zero to time of last sampling timepoint (AUC0-t)
大体时间:Approximately 12 months per patient (30 months for treatment arm)
|
Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt |
Approximately 12 months per patient (30 months for treatment arm)
|
|
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Area under the plasma concentration-time curve in one dosing interval (AUCtau)
大体时间:Approximately 12 months per patient (30 months for treatment arm)
|
Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt |
Approximately 12 months per patient (30 months for treatment arm)
|
|
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Trough observed concentrations (Ctrough/Ctau)
大体时间:Approximately 12 months per patient (30 months for treatment arm)
|
Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt |
Approximately 12 months per patient (30 months for treatment arm)
|
|
Phase 1b Combination Therapy: Blood plasma assessment to describe the concentration of rezatapopt and metabolites when rezatapopt is administered orally in combination with pembrolizumab.
大体时间:Approximately 12 months per patient (30 months for treatment arm)
|
Blood plasma concentration |
Approximately 12 months per patient (30 months for treatment arm)
|
|
Phase 1b Combination Therapy: Overall Response Rate per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review
大体时间:30 months for study (end of Phase 1b)
|
Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab |
30 months for study (end of Phase 1b)
|
|
Phase 1b Combination Therapy: Time to Response per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review
大体时间:30 months for study (end of Phase 1b)
|
Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab |
30 months for study (end of Phase 1b)
|
|
Phase 1b Combination Therapy: Duration of Response per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review
大体时间:30 months for study (end of Phase 1b)
|
Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab |
30 months for study (end of Phase 1b)
|
|
Phase 1b Combination Therapy: Disease Control Rate per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review
大体时间:30 months for study (end of Phase 1b)
|
Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab |
30 months for study (end of Phase 1b)
|
|
Phase 1b Combination Therapy: Overall Survival
大体时间:30 months for study (end of Phase 1b)
|
Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab |
30 months for study (end of Phase 1b)
|
|
Phase 1b Combination Therapy: Determine the number and type of adverse events to characterize the safety of rezatapopt
大体时间:30 months for study (end of Phase 1b)
|
Number of participants with treatment related adverse events |
30 months for study (end of Phase 1b)
|
|
Phase 1b Combination Therapy: Progression Free Survival per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review
大体时间:30 months for study (end of Phase 1b)
|
Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab |
30 months for study (end of Phase 1b)
|
|
Phase 2 Monotherapy: PK profile of rezatapopt - Time of peak concentration (Tmax)
大体时间:Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt |
Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
|
Phase 2 Monotherapy: PK profile of rezatapopt - Peak concentration (Cmax)
大体时间:Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt |
Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
|
Phase 2 Monotherapy: PK profile of rezatapopt - Area under the plasma concentration-time curve from time zero to time of last sampling timepoint (AUC0-t)
大体时间:Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt |
Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
|
Phase 2 Monotherapy: PK profile of rezatapopt - Area under the plasma concentration-time curve in one dosing interval (AUCtau)
大体时间:Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt |
Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
|
Phase 2 Monotherapy: PK profile of rezatapopt - Trough observed concentrations (Ctrough/Ctau)
大体时间:Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt |
Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
|
Phase 2 Monotherapy: Blood plasma assessment to describe the concentration of rezatapopt and metabolites when rezatapopt is administered orally.
大体时间:Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
Blood plasma concentration |
Approximately 12 months per patient (75 months for Phase 1 and Phase 2)
|
|
Phase 2 Monotherapy (Dose Expansion): Determine the number and type of adverse events to characterize the safety of rezatapopt
大体时间:34 months for study (end of Phase 2)
|
Number of participants with treatment related adverse events |
34 months for study (end of Phase 2)
|
|
Phase 2 Monotherapy (Dose Expansion): Overall Response Rate across all cohorts per RECIST v1.1 as assessed by Investigator
大体时间:34 months for study (end of Phase 2)
|
Evaluation of anti-tumor activity of rezatapopt as a single agent |
34 months for study (end of Phase 2)
|
|
Phase 2 Monotherapy (Dose Expansion): Overall Response Rate in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator
大体时间:34 months for study (end of Phase 2)
|
Evaluation of anti-tumor activity of rezatapopt as a single agent |
34 months for study (end of Phase 2)
|
|
Phase 2 Monotherapy (Dose Expansion): Time to Response in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review
大体时间:34 months for study (end of Phase 2)
|
Evaluation of anti-tumor activity of rezatapopt as a single agent |
34 months for study (end of Phase 2)
|
|
Phase 2 Monotherapy (Dose Expansion): Time to Response across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review
大体时间:34 months for study (end of Phase 2)
|
Evaluation of anti-tumor activity of rezatapopt as a single agent |
34 months for study (end of Phase 2)
|
|
Phase 2 Monotherapy (Dose Expansion): Duration of Response in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review
大体时间:34 months for study (end of Phase 2)
|
Evaluation of anti-tumor activity of rezatapopt as a single agent |
34 months for study (end of Phase 2)
|
|
Phase 2 Monotherapy (Dose Expansion): Duration of Response across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review
大体时间:34 months for study (end of Phase 2)
|
Evaluation of anti-tumor activity of rezatapopt as a single agent |
34 months for study (end of Phase 2)
|
|
Phase 2 Monotherapy (Dose Expansion): Disease Control Rate in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review
大体时间:34 months for study (end of Phase 2)
|
Evaluation of anti-tumor activity of rezatapopt as a single agent |
34 months for study (end of Phase 2)
|
|
Phase 2 Monotherapy (Dose Expansion): Disease Control Rate across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review
大体时间:34 months for study (end of Phase 2)
|
Evaluation of anti-tumor activity of rezatapopt as a single agent |
34 months for study (end of Phase 2)
|
|
Phase 2 Monotherapy (Dose Expansion): Progression Free Survival in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review
大体时间:34 months for study (end of Phase 2)
|
Evaluation of anti-tumor activity of rezatapopt as a single agent |
34 months for study (end of Phase 2)
|
|
Phase 2 Monotherapy (Dose Expansion): Progression Free Survival across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review
大体时间:34 months for study (end of Phase 2)
|
Evaluation of anti-tumor activity of rezatapopt as a single agent |
34 months for study (end of Phase 2)
|
|
Phase 2 Monotherapy (Dose Expansion): Overall Survival in ovarian cancer cohort
大体时间:34 months for study (end of Phase 2)
|
Evaluation of anti-tumor activity of rezatapopt as a single agent |
34 months for study (end of Phase 2)
|
|
Phase 2 Monotherapy (Dose Expansion): Overall Survival across all cohorts
大体时间:34 months for study (end of Phase 2)
|
Evaluation of anti-tumor activity of rezatapopt as a single agent |
34 months for study (end of Phase 2)
|
|
Phase 2 Monotherapy (Dose Expansion): Quality of life assessment
大体时间:Evaluated at every visit. 34 months for treatment arm (end of Phase 2)
|
Changes from baseline in quality of life as measured by a validated instrument, for participants 18 and older |
Evaluated at every visit. 34 months for treatment arm (end of Phase 2)
|
合作者和调查者
调查人员
- 研究主任:Marc Fellous, MD、Sr. Vice President, Clinical Development and Medical Affairs
出版物和有用的链接
一般刊物
- Papavassiliou KA, Vassiliou AG, Papavassiliou AG. Rezatapopt: A promising small-molecule "refolder" specific for TP53Y220C mutant tumors. Neoplasia. 2025 Sep;67:101201. doi: 10.1016/j.neo.2025.101201. Epub 2025 Jun 20.
- Schram AM, Fellous M, LeDuke K, Schmid A, Dumbrava EE. PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a TP53 Y220C mutation. Future Oncol. 2025 Oct;21(24):3159-3166. doi: 10.1080/14796694.2025.2557176. Epub 2025 Sep 11.
- Dumbrava EE, Shapiro GI, Parikh AR, Johnson ML, Tolcher AW, Thompson JA, El-Khoueiry AB, Vandross AL, Kummar S, Shepard DR, LeDuke K, Sheehan L, Alland L, Haque A, Jalota D, Fellous M, Schram AM. Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors. N Engl J Med. 2026 Feb 26;394(9):872-883. doi: 10.1056/NEJMoa2508820.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
- 泌尿生殖系统疾病
- 生殖器疾病
- 内分泌系统疾病
- 病理过程
- 生殖器肿瘤,男性
- 泌尿生殖系统肿瘤
- 按部位分类的肿瘤
- 肿瘤
- 生殖器疾病,男性
- 前列腺疾病
- 男性泌尿生殖系统疾病
- 女性泌尿生殖系统疾病
- 女性泌尿生殖系统疾病和妊娠并发症
- 肠道疾病
- 呼吸道疾病
- 消化道肿瘤
- 消化系统肿瘤
- 消化系统疾病
- 肠胃疾病
- 肠道肿瘤
- 直肠疾病
- 子宫疾病
- 生殖器疾病,女性
- 肺部疾病
- 内分泌腺肿瘤
- 胆道疾病
- 呼吸道肿瘤
- 胸部肿瘤
- 结肠疾病
- 肿瘤过程
- 卵巢疾病
- 附件疾病
- 生殖器肿瘤,女性
- 性腺疾病
- 皮肤病
- 乳腺疾病
- 癌,支气管癌
- 支气管肿瘤
- 子宫肿瘤
- 胆囊疾病
- 胆道肿瘤
- 病理状况、体征和症状
- 皮肤和结缔组织疾病
- 前列腺肿瘤
- 肺肿瘤
- 结直肠肿瘤
- 卵巢肿瘤
- 乳腺肿瘤
- 肿瘤转移
- 癌,非小细胞肺癌
- 头颈肿瘤
- 小细胞肺癌
- 三阴性乳腺肿瘤
- 子宫内膜肿瘤
- 胆囊肿瘤
- Pembrolizumab
其他研究编号
- PMV-586-101
- KEYNOTE-D79 (注册表标识符:Merck, Sharp & Dohme, LLC)
- MK-3475-D79 (注册表标识符:Merck, Sharp & Dohme, LLC)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.